osimertinib
astrazeneca
['adaura', 'aura ,(-laura)']
more patients in the placebo arm of adaura got egfr tkis, but they mostly got the inferior tkis, instead of osi, which is a far better drug. less than half got osi at progression and because of that i don't think it "dispels" the notion of adjuvant vs at recurrence.
#asco23 
Geriatric Oncologist @incmnszmx #gerionc, Global Oncology. @ASCO BOD 20-24, FASCO. PhD @UNAM_MX Opinions my own. 🇲🇽 https://t.co/GruVowjxCI…